Cannabis Law Report

AUGUST 12, 2022

. – August 11, 2022) – MOTAGON, a pharmaceutical company based in Prague and specializing in medical cannabis, has secured a ground-breaking agreement with Europe’s biggest indoor cannabis producer and one of the first cannabis extracts and formulations producers PHCANN INTERNATIONAL. ”

Extraction 52

Extraction Pharmaceutical Patients THC 52

NORML

FEBRUARY 14, 2019

SB1719 allows “registered agents” for those patients physically unable to pick up or receive delivery of their medical cannabis, like those in hospice, assisted living facilities, and those who rely on home healthcare providers. Virginia NORML members meet with Senator Dave Marsden. “I am proud to be part of this effort.”

Access 200

Access Patients Legislation Medicine 200

Cannabis Law Report

JUNE 17, 2021

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) raised its full-year 2021 financial guidance based on the acquisition of GW Pharmaceuticals, which was bought on May 5, 2021. regulatory approval, and our new cannabinoid research platform,” said Renée Galá, the chief financial officer of Jazz Pharmaceuticals.

Pharmaceutical 108

Pharmaceutical Clinical Trials Therapy Programs 108

Cannabis Law Report

NOVEMBER 23, 2020

22 Nov – Blurb… Since 2019, Medicinal Cannabis Clinics has facilitated over 4,000 medical consultations with pre-screened eligible patients and has shown continued month-on-month growth.… The post MGC Pharmaceuticals acquires Australian telehealth platform Medicinal Cannabis Clinics first appeared on Cannabis Law Report.

Pharmaceutical 59

Pharmaceutical Medicine Patients Cannabis 59

MMJ Recs

FEBRUARY 3, 2024

In recent years, the landscape of medical marijuana laws has evolved, presenting new opportunities and challenges for patients, healthcare providers, and industry stakeholders. These laws outline the parameters for the cultivation, distribution, and use of medical cannabis within the city.

Legislation 52

Legislation Law Marijuana Dispensary 52

Cannabis Law Report

AUGUST 10, 2021

GW was initially granted marketing authorisation for this medicine in the UK in September 2019 as an adjunctive therapy for seizures associated with Lennox Gastaut syndrome (LGS) or Dravet syndrome, in conjunction with clobazam, for patients two years of age and older.

Pharmaceutical 98

Pharmaceutical Treatment Epilepsy Research and Development 98

Veriheal

FEBRUARY 21, 2023

Despite notable advances in MMJ research over the last decade, scientists have found that some states’ restrictions on qualifying conditions prevent millions of patients from getting the treatments they need—robbing them of potential relief offered by cannabinoid therapies. How Do MMJ Restrictions Affect Patients and Doctors?

Access 98

Access Patients Chronic Pain Conditions 98

The Cannigma

JUNE 1, 2021

Possessing cannabis is illegal in France, although in 2020, the country changed the law so that the punishment is now a €200 fine. Possessing cannabis is illegal in France, although in 2020, the country changed the law so that the punishment is now a €200 fine. Shutterstock. France’s (experimental) medical cannabis program.

Law 113

Law Epilepsy Programs Patients 113

The Cannigma

DECEMBER 4, 2022

Another draft law was introduced in 2019 to expand the program; as of 2022, it was still in draft in a chamber of government. Patients can be prescribed medical marijuana in the form of pharmaceuticals, like Sativex. However, this legalization is a technicality, as there is no established medical program for patients to join.

Law 59

Law Seed-To-Sale Programs Tincture 59

Cannabis Law Report

DECEMBER 15, 2021

Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX: WEED) (NASDAQ: CGC ) has entered into an agreement to divest its subsidiary business, C³ Cannabinoid Compound Company GmbH (“C3”), to Dermapharm Holding SE (“Dermapharm”) (WKN: A2GS5D, ISIN: DE000A2GS5D8), a European pharmaceutical company headquartered in Grünwald, Germany.

Pharmaceutical 52

Pharmaceutical Cannabinoids Business Extraction 52

MMJ Recs

MAY 15, 2022

This initial MMJ legislation only allowed patients suffering from intractable epilepsy to use cannabis oil. In 2020, the law changed to allow patients with any medical condition to receive a doctor’s recommendation to use and purchase medical marijuana products containing a maximum 10 milligrams of THC.

Patients 52

Patients Marijuana Pharmaceutical Dispensary 52

Puff Puff Post

MARCH 10, 2020

SOURCE InMed Pharmaceuticals Inc. InMed has conducted preclinical pharmacology studies that suggest CBN in INM-755 may help relieve hallmark EB symptoms, including inflammation and pain, as well potentially restore the integrity of the skin in a subset of EB Simplex patients.

Clinical Trials 84

Clinical Trials Pharmaceutical Research and Development Cannabinoids 84

Cannabis Law Report

AUGUST 22, 2021

“The Janus particle solution will allow for time-released and combined therapies to be administered to patients, targeting specific indications. is using cutting-edge delivery technologies to develop safe and effective psychedelic pharmaceutical medicines. ” About Psycheceutical, Inc. Psycheceutical, Inc.

Pharmaceutical 98

Pharmaceutical Medicine Research and Development Therapy 98

SpeedWeed

APRIL 9, 2021

Although this survey is specifically focused on Texas’ medical marijuana program, it also supports other research showing that cannabis can serve as an effective replacement for pharmaceuticals. This law allows a limited number of patients to use CBD-based medicine with no more than 0.5 percent THC content.

Pharmaceutical 52

Pharmaceutical Chronic Pain Programs Patients 52

Cannabis Law Report

AUGUST 27, 2021

The Edmonton, Alberta-based cannabis giant also said that its subsidiary and Ethypharm were selected by the National Agency for the Safety of Medicines and Health Products to supply the entire medical cannabis dried flower range sourced from the company’s EU GMP facility in Denmark Aurora Nordic to French patients as part of the program.

Patients 105

Patients Programs Pharmaceutical Compliance 105

Cannabis Law Report

JULY 7, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Current TNF-a inhibitors available today, while effective, come with an array of adverse effects and concerns for patients,” said Adam Kaplin, M.D., About MyMD Pharmaceuticals, Inc. Company plans to initiate Phase II trial with a leading academic institution.

Pharmaceutical 105

Pharmaceutical Data Clinical Trials Research and Development 105

Cannabis Law Report

AUGUST 17, 2021

reduction in 28-day seizure frequency relative to baseline in tuberous sclerosis complex (TSC) patients (n=23). reduction was observed in focal seizures (n=19), the most common seizure type in TSC patients. Phase 3 planning for TrustTSC trial ongoing with first patient expected to be enrolled in Q4 2021. RADNOR, Pa.–(BUSINESS

Pharmaceutical 98

Pharmaceutical Clinical Trials Treatment Patients 98

Cannabis Law Report

JUNE 23, 2021

Valcon Medical A/S Announces Receipt of EU GMP Certification and Start of Commercial Production for Pharmaceutical-Grade Cannabis Concentrates, Intermediary Products, and Medical Formulations (PRNewsfoto/Valcon Medical A/S).

Pharmaceutical 86

Pharmaceutical Concentrates Extraction Medicine 86

Cannabis Law Report

SEPTEMBER 24, 2019

Here is the BBC report and below you will find the full press release from GW Pharmaceuticals. T he EU has approved for the first time the use of a medicinal cannabis product aimed at patients with two rare, but severe, forms of childhood epilepsy. What about other medical cannabis products? ” Source BBC: [link]. PDF Version.

Pharmaceutical 55

Pharmaceutical Epilepsy Research and Development Medicine 55

The Cannigma

OCTOBER 14, 2022

However, the laws don’t differentiate between soft drugs and hard drugs. Established in 2016 by a citizen’s initiative, patients can purchase cannabis-based medicines like Sativex to treat a number of approved conditions including multiple sclerosis, spine injuries, and neuropathic pain. San Marino medical marijuana program.

Law 56

Law Clinical Trials Research and Development Recreational 56

Cannabis Law Report

AUGUST 24, 2021

BALTIMORE–(BUSINESS WIRE)– $MYMD — MyMD Pharmaceuticals, Inc. Thus, there is a great need to develop new and effective therapeutics for treating patients. About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc.

Pharmaceutical 98

Pharmaceutical Clinical Trials Chronic Pain CBD 98

Cannabis Law Report

JUNE 1, 2022

Pharmadrug GmbH has been active worldwide for almost 40 years as a manufacturer and wholesaler of medicinal products and active pharmaceutical ingredients. Our team in Europe is excited to join forces with new colleagues from Pharmadrug GmbH, with their valuable expertise in the German pharmaceutical market.”

Pharmaceutical 52

Pharmaceutical Medicine Extraction Cannabinoids 52

Cannabis Law Report

JUNE 5, 2019

Press Release: Thailand Government Pharmaceutical Organization. The Pharmaceutical Organization, Department of Medical Affairs, signed a joint research on standard quality medical marijuana extracts for patients with chemo-allergic cancer, epilepsy, muscle contraction in patients with deteriorating nerve sheaths.

Pharmaceutical 40

Pharmaceutical Extraction Epilepsy Research and Development 40

Veriheal

FEBRUARY 11, 2021

Cannabis has been identified as a potentially effective strategy to decrease opiate usage and the survey wanted to determine how the use of medical cannabis affects opioid prescription usage among patients with chronic pain. They conducted an online survey of patients from three medical practice sites.

Chronic Pain 85

Chronic Pain Patients Clinical Trials Treatment 85

Cannabis Law Report

DECEMBER 9, 2021

08, 2021 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. In addition to his consulting and directorial responsibilities, he maintains an active research program directed towards improving outcomes for stroke patients. Moreau CEO of Algernon Pharmaceuticals Inc. “We About Algernon Pharmaceuticals Inc. .

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Canna Law Blog

MARCH 6, 2023

The Regulation implements the provisions of Law No. 30681 and Law No. Licenses to import cannabis and/or market cannabis derivatives may be granted to pharmaceutical laboratories and droguerías , duly authorized to operate by the Peruvian government. In addition, licenses are available for accredited patient associations.

Pharmaceutical 89

Pharmaceutical Patients Environment Cannabis 89

Cannabis Law Report

DECEMBER 3, 2021

–(BUSINESS WIRE)– $MRNS #MarinusPharma — Marinus Pharmaceuticals, Inc. Chief Executive Officer of Marinus Pharmaceuticals. “We Chief Executive Officer of Marinus Pharmaceuticals. “We Webcast to be held Monday, December 6 at 1:00 p.m. ET (12:00 p.m. RADNOR, Pa.–(BUSINESS

Epilepsy 52

Epilepsy Pharmaceutical Data Clinical Trials 52

SpeedWeed

AUGUST 9, 2021

It’s an issue around the world: Governments continue to approve expensive, cannabis-based pharmaceutical products for medicinal use, while cultivation of the plant remains illegal for patients (and their families) to grow at home. Later that year, Peruvian politicians passed the country’s first medical marijuana laws. .

Law 52

Law Legalization Hydroponic Medicine 52

Cannabis Law Report

JULY 23, 2019

(TSXV: LG and OTC-QB: LGGCF) (“ LGC ”) is pleased to announce that it has paid the 2 nd Tranche, as contractually agreed, in acquiring an equity interest in the Italian pharmaceutical company, Freia Farmaceutici Srl (“Freia”). This EU pharmaceutical entity is an optimal addition to LGC. ” NOTE TO EDITORS.

Pharmaceutical 45

Pharmaceutical Seed-To-Sale Compliance Compliance 45

Cannabis Law Report

JANUARY 6, 2022

An especially worrisome development is the efforts of pharmaceutical companies to patent psilocybin products. This blog post will explain how psilocybin patenting and other factors could make Oregon’s psilocybin program prohibitively expensive for low-income patients, and how big pharma is maneuvering to monopolize psychedelic therapy.

Access 52

Access Patients Research and Development Treatment 52

MMJ Recs

NOVEMBER 17, 2023

This article explores the profound impact of MMJ on Maryland communities, shedding light on the medical marijuana benefits experienced by patients and the positive effects it has had on the state’s communities. It has improved the quality of life for those dealing with chronic pain, nausea, seizures, and other medical conditions.

Chronic Pain 98

Chronic Pain Therapy Research and Development Treatment 98

Cannabis Law Report

JULY 9, 2021

The state of the law on psychedelic substances is in flux. Patients would participate in therapy sessions to prepare for the use of psychedelics, after which the substances would be administered under the guidance and supervision of trained medical professionals. Published Via JD Supra.

Law 105

Law Therapy Clinical Trials Research and Development 105

Puff Puff Post

MARCH 10, 2020

SOURCE InMed Pharmaceuticals Inc. InMed has conducted preclinical pharmacology studies that suggest CBN in INM-755 may help relieve hallmark EB symptoms, including inflammation and pain, as well potentially restore the integrity of the skin in a subset of EB Simplex patients.

Clinical Trials 40

Clinical Trials Pharmaceutical Research and Development Cannabinoids 40

SpeedWeed

MARCH 30, 2021

THE UK’s first National Health Service patients registry will start collating data from Thursday this week in a significant move for medical cannabis in the country. An estimated 250 patients a month are said to be prescribed cannabis medicines through the NHS compared to over 2,500 in the UK’s private sector. Step In Right Direction.

Data 52

Data Patients Clinical Trials Business 52

Cannabis Law Report

SEPTEMBER 24, 2020

Here’s the press release …… GW Pharmaceuticals receives Australian Therapeutic Goods Administration (TGA) approval for EPIDYOLEX® (cannabidiol) for the treatment of seizures in patients with two … Read More.

Pharmaceutical 98

Pharmaceutical Treatment Patients Law 98

Cannabis Law Report

JULY 21, 2019

FWB: 8K51)(OTC: WLDCF) (the “Company” or “ ICC ” or “ International Cannabis”) is pleased to announce that the Company has entered into an exclusive supply and commercial rights agreement (the “Agreement”) with licensed New Zealand medical cannabis company, NUBU Pharmaceuticals (“NUBU”). (CSE: WRLD.U)(FWB:

Pharmaceutical 40

Pharmaceutical THC CBD Supply Chain 40

Cannabis Law Report

JULY 19, 2019

FWB: 8K51)(OTC: WLDCF) (the “Company” or “ ICC ” or “ International Cannabis”) is pleased to announce that the Company has entered into an exclusive supply and commercial rights agreement (the “Agreement”) with licensed New Zealand medical cannabis company, NUBU Pharmaceuticals (“NUBU”). (CSE: WRLD.U)(FWB:

Pharmaceutical 40

Pharmaceutical THC CBD Supply Chain 40